SCHEMBL31193286

SCHEMBL31193286

Clc1cccc(CNc2c(-c3ccncn3)nc3cnccn23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK9 P50750 1/20 0.55
▸ PLAU P00749 1/20 0.49
▸ SALL4 Q9UJQ4 2/20 0.47
▸ NR1H4 Q96RI1 4/20 0.44
▸ BRD4 O60885 1/20 0.44
▸ FLT3 P36888 2/20 0.42
▸ TRIM24 O15164 2/20 0.42
▸ TRIM33 Q9UPN9 1/20 0.41
▸ BRAF P15056 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KCNN3 Q9UGI6 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CASP1 P29466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31193288 0.86 CDK9 (0.60) CDK9SALL4NR1H4BRD4TRIM24
SCHEMBL31193423 0.85 CDK9 (0.76) CDK9PLAUSALL4NR1H4BRD4
SCHEMBL27075690 0.83 CDK9 (0.56) CDK9PLAUSALL4NR1H4BRD4
SCHEMBL31193353 0.82 BRAF (0.53) BRAFKDM4EALDH1A1GAAHPGD
SCHEMBL20889554 0.80 CDK9 (0.53) CDK9PLAUSALL4NR1H4BRD4
SCHEMBL20889542 0.79 SALL4 (0.55) CDK9PLAUSALL4NR1H4BRD4
SCHEMBL20889552 0.76 SALL4 (0.81) CDK9PLAUSALL4BRD4TRIM24
SCHEMBL31193343 0.72 BRD4 (0.44) CDK9SALL4BRD4TRIM24TRIM33
SCHEMBL31193297 0.72 GAA (0.53) BRAFKDM4EALDH1A1GAAHPGD
SCHEMBL31193285 0.72 GAA (0.48) BRAFKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12129257-B1 Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors King Faisal University (SA) 2024-10-29 — — US claimed
US-12129257-B1 Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors King Faisal University (SA) 2024-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129257-B1 Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors CSNK2A1, CSNK2A2, CSNK1A1 CDK9 126/4885PLAU 4652/4885SALL4 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback